TALARIS THERAPEUTICS INC (TALS) Fundamental Analysis & Valuation

NASDAQ:TALS • US87410C1045

Current stock price

2.72 USD
-0.02 (-0.73%)
At close:
2.75 USD
+0.03 (+1.1%)
After Hours:

This TALS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. TALS Profitability Analysis

1.1 Basic Checks

  • In the past year TALS has reported negative net income.
  • TALS had a negative operating cash flow in the past year.
TALS Yearly Net Income VS EBIT VS OCF VS FCFTALS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -20M -40M -60M

1.2 Ratios

  • TALS has a Return On Assets (-46.99%) which is comparable to the rest of the industry.
  • TALS's Return On Equity of -50.38% is fine compared to the rest of the industry. TALS outperforms 64.29% of its industry peers.
Industry RankSector Rank
ROA -46.99%
ROE -50.38%
ROIC N/A
ROA(3y)-24.01%
ROA(5y)N/A
ROE(3y)-25.36%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TALS Yearly ROA, ROE, ROICTALS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 -10 -20 -30 -40

1.3 Margins

  • TALS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TALS Yearly Profit, Operating, Gross MarginsTALS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. TALS Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for TALS has been increased compared to 1 year ago.
  • TALS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TALS Yearly Shares OutstandingTALS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 10M 20M 30M 40M
TALS Yearly Total Debt VS Total AssetsTALS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

  • TALS has an Altman-Z score of 4.50. This indicates that TALS is financially healthy and has little risk of bankruptcy at the moment.
  • TALS has a Altman-Z score of 4.50. This is amongst the best in the industry. TALS outperforms 81.89% of its industry peers.
  • There is no outstanding debt for TALS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.5
ROIC/WACCN/A
WACCN/A
TALS Yearly LT Debt VS Equity VS FCFTALS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 100M 200M

2.3 Liquidity

  • A Current Ratio of 15.41 indicates that TALS has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 15.41, TALS belongs to the best of the industry, outperforming 87.38% of the companies in the same industry.
  • A Quick Ratio of 15.41 indicates that TALS has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 15.41, TALS belongs to the top of the industry, outperforming 87.38% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 15.41
Quick Ratio 15.41
TALS Yearly Current Assets VS Current LiabilitesTALS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. TALS Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 24.79% over the past year.
EPS 1Y (TTM)24.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • TALS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.08% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y22.08%
EPS Next 2Y18.99%
EPS Next 3Y3.04%
EPS Next 5Y9.08%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TALS Yearly Revenue VS EstimatesTALS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 100M 200M 300M
TALS Yearly EPS VS EstimatesTALS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 2 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. TALS Valuation Analysis

4.1 Price/Earnings Ratio

  • TALS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TALS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TALS Price Earnings VS Forward Price EarningsTALS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TALS Per share dataTALS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.99%
EPS Next 3Y3.04%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. TALS Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 55.58%, TALS is a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 1.28, TALS pays a better dividend. On top of this TALS pays more dividend than 99.83% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.89, TALS pays a better dividend.
Industry RankSector Rank
Dividend Yield 55.58%

5.2 History

  • TALS is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
TALS Yearly Dividends per shareTALS Yearly Dividends per shareYearly Dividends per share 2023 0.5 1 1.5

5.3 Sustainability

DPN/A
EPS Next 2Y18.99%
EPS Next 3Y3.04%
TALS Yearly Income VS Free CF VS DividendTALS Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2019 2020 2021 2022 -20M -40M -60M

More info and screens

Find the best dividend stocksShow peers with best dividend

TALS Fundamentals: All Metrics, Ratios and Statistics

TALARIS THERAPEUTICS INC

NASDAQ:TALS (10/19/2023, 8:10:51 PM)

After market: 2.75 +0.03 (+1.1%)

2.72

-0.02 (-0.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14
Earnings (Next)11-08
Inst Owners0%
Inst Owner Change0%
Ins Owners11.37%
Ins Owner Change0%
Market Cap116.44M
Revenue(TTM)N/A
Net Income(TTM)-74.77M
Analysts43.33
Price Target20.4 (650%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 55.58%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-51.26%
Min EPS beat(2)-51.26%
Max EPS beat(2)-51.26%
EPS beat(4)2
Avg EPS beat(4)-12.68%
Min EPS beat(4)-51.26%
Max EPS beat(4)11.96%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)60%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.78
P/tB 0.78
EV/EBITDA N/A
EPS(TTM)-1.79
EYN/A
EPS(NY)-1.05
Fwd EYN/A
FCF(TTM)-1.4
FCFYN/A
OCF(TTM)-1.38
OCFYN/A
SpS0
BVpS3.47
TBVpS3.47
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -46.99%
ROE -50.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-24.01%
ROA(5y)N/A
ROE(3y)-25.36%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 95.92%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.41
Quick Ratio 15.41
Altman-Z 4.5
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)299.29%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.65%
EPS Next Y22.08%
EPS Next 2Y18.99%
EPS Next 3Y3.04%
EPS Next 5Y9.08%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-2.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year40.82%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-50.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-52.19%
OCF growth 3YN/A
OCF growth 5YN/A

TALARIS THERAPEUTICS INC / TALS Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for TALARIS THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to TALS.


What is the valuation status for TALS stock?

ChartMill assigns a valuation rating of 0 / 10 to TALARIS THERAPEUTICS INC (TALS). This can be considered as Overvalued.


How profitable is TALARIS THERAPEUTICS INC (TALS) stock?

TALARIS THERAPEUTICS INC (TALS) has a profitability rating of 1 / 10.


Can you provide the financial health for TALS stock?

The financial health rating of TALARIS THERAPEUTICS INC (TALS) is 8 / 10.


Can you provide the expected EPS growth for TALS stock?

The Earnings per Share (EPS) of TALARIS THERAPEUTICS INC (TALS) is expected to grow by 22.08% in the next year.